HRTXHealthcare · BiotechnologyThe 2 Wall Street analysts covering Heron Therapeutics, Inc. hold a median 12-month price target of $7 — +2118.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 45 of 100 as at 11 Sept 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Heron Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (95): The business earns solid, repeatable profits on what it owns.
Momentum (3): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on HRTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +2118.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Aug 2026 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 3 June 2026 | HC Wainwright & Co. | Maintains | Buy | $4.00 → $2.00 |
| 3 June 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 3 June 2026 | Needham | Downgrade | Hold | — |
| 3 June 2026 | Needham | Downgrade | Hold | — |
| 9 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 Aug 2025 | Needham | Maintains | Buy | — |
| 9 June 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 11 Apr 2025 | Needham | Reiterates | Buy | — |
| 28 Feb 2025 | Needham | Reiterates | Buy | — |
| 4 Dec 2024 | Needham | Reiterates | Buy | — |
| 13 Nov 2024 | Needham | Maintains | Buy | — |
| 25 Sept 2024 | Needham | Reiterates | Buy | — |
| 7 Aug 2024 | Needham | Reiterates | Buy | — |
| 13 June 2024 | Rodman & Renshaw | Initiates | Buy | — |
| 16 May 2024 | Needham | Reiterates | Buy | — |
| 8 May 2024 | Needham | Reiterates | Buy | — |
| 23 Apr 2024 | Capital One | Initiates | Overweight | — |
| 11 Apr 2024 | Needham | Reiterates | Buy | — |
| 13 Mar 2024 | Needham | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HRTX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Heron Therapeutics, Inc. returned −75.4% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 86% of US stocks
Cheaper than 85% of US stocks
Cheaper than 9% of US stocks
Cheaper than 89% of US stocks
Higher than 30% of US stocks
Higher than 82% of US stocks
Higher than 27% of US stocks
Higher than 15% of US stocks
Higher than 10% of US stocks
Higher than 35% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Heron Therapeutics, Inc. has a market value of $59.9M and an enterprise value of $166.6M.
Revenue in the twelve months to 30 June 2026: $151.2M. The latest quarter grew 1.3% year on year.
Net income over the same four quarters: −$34.0M, a −22.5% net margin.
Diluted earnings per share, trailing twelve months: $−0.19.
Free cash flow in the twelve months to 30 June 2026: −$12.1M.
Trailing P/E: −2.6×; forward P/E: −2.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Heron Therapeutics, Inc. employs 128 people — $1.2M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Heron Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published a transcript of Heron Therapeutics' Q2 2026 earnings call. The item presents the company's earnings call transcript for the quarter.
Why it matters — An HRTX watcher would care because the earnings call transcript provides direct insight into the company's Q2 2026 financial results and management commentary.
Heron Therapeutics reported a Q2 loss of $0.03 per share, wider than the Zacks Consensus Estimate of a $0.02 loss and matching the year-ago quarter's $0.02 per-share loss. Revenue also lagged expectations.
Why it matters — The wider-than-expected quarterly loss and revenue miss signal the company's near-term financial performance fell short of analyst forecasts.
Heron Therapeutics reported second-quarter net revenue of $37.7 million, up from $34.7 million in the first quarter and $37.2 million in the same period last year. Management said sales of its key products came in below its internal expectations.
Why it matters — The revenue growth is offset by management's disclosure that key product sales fell short of internal expectations, which is relevant to HRTX watchers assessing the company's performance.
Heron Therapeutics announced it will release its second quarter 2026 financial results and host a conference call on August 10, 2026.
Why it matters — The call and webcast will provide investors and analysts with updates on Heron's quarterly financial performance and recent business highlights.
The 2 Wall Street analysts covering Heron Therapeutics, Inc. have a median 12-month price target of $7, with estimates ranging from $5 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Heron Therapeutics, Inc., 0 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Heron Therapeutics, Inc. 45 out of 100 across roughly 4,600 US stocks as at 11 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 11 Sept 2026, Heron Therapeutics, Inc. ranks 45 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (95 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +2118.7% from the last close, and Ticker Nerd's factor model ranks Heron Therapeutics, Inc. 45 out of 100 as at 11 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Heron Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HRTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $9 over the next 12 months.
Heron Therapeutics, Inc. returned -75.4% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and marketing therapies for acute care and oncology supportive care.
The most recent item we track (Seeking Alpha, 10 Aug 2026): "Heron Therapeutics, Inc. (HRTX) Q2 2026 Earnings Call Transcript". Seeking Alpha published a transcript of Heron Therapeutics' Q2 2026 earnings call. The item presents the company's earnings call transcript for the quarter.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and marketing therapies for acute care and oncology supportive care. The company’s current portfolio includes products used to help manage post-surgical pain and to prevent nausea and vomiting associated with surgery and cancer treatment. Its marketed medicines are designed for use in clinical settings and are sold primarily through healthcare providers, hospitals, and other medical institutions. Heron Therapeutics relies on proprietary drug delivery and formulation capabilities to support its branded prescription products, which serve specialized patient needs in perioperative care and oncology. The company operates in the U.S. specialty pharmaceutical market and is positioned around targeted treatments that address common complications of medical procedures and cancer therapy.
CEO Mr. Craig Alexander Collard · 128 employees · United States · https://www.herontx.com
